Atrandi Biosciences

Executive Summary

Atrandi Biosciences is a private biotechnology company based in Leiden, the Netherlands, pioneering single-cell analysis with its proprietary Semi-Permeable Capsules (SPCs) technology. Founded in 2018, the company addresses a critical bottleneck in genomics and diagnostics: the ability to process thousands of individual cells simultaneously while preserving single-cell resolution. Traditional methods often require complex microfluidics or are limited in throughput; Atrandi's SPCs enable bulk reactions on isolated cells, dramatically simplifying workflows and reducing costs. This innovation is particularly relevant for applications such as rare cell detection, drug screening, and personalized medicine, where high-throughput single-cell data is essential. While the company has not disclosed funding rounds or partnerships, its technology has the potential to disrupt the growing single-cell analysis market, projected to exceed $5 billion by 2030. Atrandi's platform could compete with established players like 10x Genomics and Fluidigm by offering a simpler, more scalable solution. The company remains in a development phase, with no commercial products yet announced, but its strong IP position and focus on user-friendly design position it well for future growth. Key risks include scale-up challenges, competition, and the need for commercial validation.

Upcoming Catalysts (preview)

• Q4 2026Commercial launch of first SPC-based product70% success
• Q3 2026Strategic partnership with a major genomics or pharma company50% success
• Q4 2026Series A funding round announcement60% success